Solid Biosciences Inc.

Solid Biosciences Inc. is a U.S.-based biopharmaceutical company focused on developing gene therapies and related technologies for rare neuromuscular and cardiac diseases. Its pipeline includes candidates such as SGT-003, SGT-212, SGT-501, and SGT-002, supported by preclinical, clinical, manufacturing, and regulatory activities.

6.14

6.14

— Solid Biosciences Inc.
%
Duchenne gene therapy programs40% Development of gene therapy candidates aimed at Duchenne muscular dystrophy.
Cardiac gene therapy programs25% Programs targeting CPVT and other inherited cardiomyopathies.
Preclinical and clinical development20% Discovery, laboratory testing, and clinical trial execution for pipeline candidates.
Manufacturing and CMC support10% Third-party manufacturing, process scale-up, and drug product supply for studies.
Adjacent technologies and assays5% Supporting technologies used to advance research and development programs.

Solid Biosciences primarily serves patients through the development of therapies for rare genetic diseases, with...

  • Rare disease patientsprimary

    Patients with Duchenne muscular dystrophy, CPVT, and other inherited disorders targeted by the pipeline.

  • Specialty physicians and treatment centersprimary

    Neuromuscular and cardiac specialists who would administer or refer patients for approved therapies.

  • Clinical trial ecosystemprimary

    CROs, investigators, and trial sites that conduct preclinical and clinical studies for the company.

  • Potential commercial payerssecondary

    Insurers and health systems that would reimburse future approved gene therapies.

  • Strategic collaboratorssecondary

    Licensing and collaboration partners that may fund or support development and commercialization.

Solid Biosciences is headquartered in the United States and conducts most of its development, regulatory, and corporate...

  • •Headquartered in the United States
  • •Primary regulatory exposure is to the U.S. FDA
  • •Clinical development is centered on U.S.-based programs
  • •Manufacturing relies on third-party CDMOs, potentially global
  • •Future commercialization would likely begin in major U.S. markets

The company’s strategy is to advance its gene therapy pipeline through research, clinical trials, and regulatory...

01
Advance lead gene therapy candidates through clinical developmentshort-term

Clinical proof-of-concept is the main value driver for a pre-commercial biotech.

02
Strengthen manufacturing and supply chain capabilitiesshort-term

Gene therapies require reliable cGMP manufacturing and scalable supply for trials and launch.

03
Expand pipeline and technology basemedium-term

Broader programs can diversify scientific risk and create partnering opportunities.

04
Prepare for eventual commercializationmedium-term

Approved gene therapies require sales, marketing, distribution, and market-access capabilities.

Solid Biosciences faces the typical risks of a clinical-stage biotech: uncertain trial outcomes, regulatory delays, and...

critical

Clinical development failure

Pipeline value depends on successful trial results and acceptable safety/efficacy.

Scope
INSPIRE DUCHENNE, SGT-212, SGT-501, SGT-003
Materiality
high
high

Regulatory delay or rejection

Gene therapies require extensive FDA review and may need extra studies or holds lifted.

Scope
Marketing approvals and clinical trial authorizations
Materiality
high
high

Manufacturing and quality risk

The company relies on third-party manufacturers for cGMP supply and scale-up.

Scope
CDMO production of clinical and future commercial material
Materiality
high
high

Financing risk

The business expects continued losses and may need additional capital to fund operations.

Scope
Equity, debt, licensing, or collaboration funding
Materiality
high
medium

Competitive pressure

Larger biopharma and other gene therapy developers may reach market first or with better data.

Scope
Duchenne, CPVT, and other cardiomyopathy programs
Materiality
medium
Accrued research and development expenses
Can shift quarterly operating expense timing
Equity-based compensation
Affects reported operating loss without immediate cash outflow
Derivative liabilities
Can add volatility to other income/expense
Clinical and manufacturing accruals
Can materially affect period-to-period comparability

Forte Biosciences, Inc.

FBRX · Pharmaceutical Preparations

Cogent Biosciences, Inc.

COGT · Pharmaceutical Preparations

Neurogene Inc.

NGNE · Pharmaceutical Preparations

MUSTANG BIO, INC.

MBIO · Pharmaceutical Preparations

ASSEMBLY BIOSCIENCES, INC.

ASMB · Pharmaceutical Preparations

Solid Power, Inc.

SLDP · Miscellaneous Electrical Machinery, Equipment & Supplies

: 29/04/2026